Exicure licenses cavrotolimod patents to Bluejay for hepatitis treatment

EXICURE, INC.

Bluejay receives exclusive license in hepatitis field to Exicure's patents; small upfront payment made.
Exicure eligible for modest royalties on future net sales of licensed technology.
Exicure responsible for prosecution and maintenance of licensed patents.
Cavrotolimod historically developed for oncology; repurposed for hepatitis by Bluejay.
Bluejay is a private clinical-stage biopharma focused on viral and liver diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.